Business Wire

CB Pharma Acquisition Corp. Announces Approval of Proposals to Extend Time to Complete Initial Business Combination

NEW YORK--(BUSINESS WIRE)--CB Pharma Acquisition Corp. (“CB Pharma”) (NASDAQ:CNLM; CNLMU; CNLMR; CNLMW) announced today that it held its extraordinary general meeting of shareholders and that at such ...
EurekAlert!

Combination of new drug, CB-839, with everolimus stops advanced kidney tumors growing

Munich, Germany: The first drug to target a key enzyme that cancer cells need to keep them alive has shown that it is effective in controlling disease in patients with advanced kidney cancer when it ...
Business Insider

McDermott and CB&I Stockholders Approve Proposed Combination

HOUSTON and THE WOODLANDS, Texas, May 02, 2018 (GLOBE NEWSWIRE) -- McDermott International, Inc. (“McDermott”) (NYSE:MDR) and CB&I (NYSE:CBI) today announced both companies have received the necessary ...
Business Insider

McDermott and CB&I Announce Early Termination of Hart-Scott-Rodino Waiting Period for Proposed Combination

HOUSTON and THE WOODLANDS, Texas, Jan. 25, 2018 (GLOBE NEWSWIRE) -- McDermott International, Inc. (NYSE:MDR) and CB&I (NYSE:CBI) today announced that the Federal Trade Commission has granted early ...
ascopubs.org

CANTATA: A randomized phase 2 study of CB-839 in combination with cabozantinib vs. placebo with cabozantinib in patients with advanced/metastatic renal cell carcinoma.

Optimized management of nivolumab (NIVO) and ipilimumab (IPI) in advanced renal cell carcinoma (OMNIVORE): A response-based phase II study. Background: Glutamine utilization is a metabolic pathway ...